Scholar Rock’s Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection

All NewsSeptember 23, 2025

FDA cites Catalent Indiana issues in Scholar Rock’s SMA drug review; European approval decision expected in 2026, with Germany as the launch market.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent